Allogeneic hematopoietic cell transplantation (HCT) is the curative therapy for patients with malignant hematologic diseases. However, for the patients with high risk or relapse, the 3-year overall survival (OS) rates were only about 20% for AML and 15% for ALL after myeloablative HCT.
1,2 HLA haploidentical HCT (Haplo-HCT) has become an effective alternative to treat those patients who lack a suitable HLA matched donor in China, however, relapse and severe GvHD are still major causes of mortality in Haplo-HSCT. 3 Previously, we proposed a new concept of tumorablative allogeneic HCT (TAHCT) and used it to treat the adult leukemia at high risk or in relapse. The preliminary results have demonstrated that it reduced the relapse to about 20% in these patients. 4, 5 Here we report the results of using TAHCT to treat the children patients with high-risk or relapsed hematologic malignancies.
Twenty-six patients aged median 7-year-old (range, 1.2-14), including 14 males and 12 females, were enrolled. Seven patients had AML, 13 ALL, 2 non-Hodgkin lymphoma (NHL) (T-lymphoblastic lymphoma (LBL)), and the other 3 myelodysplastic syndrome (MDS)/AML and 1 juvenile myelomonocytic leukemia with PTPN11 mutation. HLA for A, B, C, DRB1 and DQB1 was determined by high resolution DNA typing. Among 26 patient/ donor pairs, 21 were mismatched in 5/10 HLA allele, 3 in 4/10 and 2 in 3/10 or 1/10.
The further regimen was based on our previous protocol for adult HSCT. 5 Briefly, two regimens were included: regimen A, for patients who were older than 3 years or with extramedullary involvement: X (which is the effective anthracycline sought from the patient's chemotherapy history, for example, idarubicin 10 mg/m .day (day − 13 to − 9), Ara-C 0.5-2.0 g/m 2 .12 h (day − 13 to − 9), rhG-CSF 5 ug/kg.day (day − 14 to − 9), teniposide (VM-26) 300 mg/m 2 .day (day − 8), TBI with 4.5 Gy/day (days − 7 to − 6), CY 40 mg/kg.day (days − 5 to − 4) and rabbit ATG (Fresenius) 5 mg/kg.day (days − 5 to − 2). The day of bone marrow (BM) and PBSC infusion was designated as day 1 and day 2. Regimen B for the other patients, in which, Busulfex 0.8 − 1.1 mg/kg every 6 hours for 3 days instead of TBI, others were same to regimen A. BM and PBSC were both selected for HSCT as the source of cellular rescue. PBSC were obtained by apheresis with CS-3000 plus after the SC administration of rhG-CSF 5-10 μg/ kg.day for 5 days. The median hematopoietic cell dose infusion was 10.59 × 10 8 /kg mononuclear cells (range, 6.36-13.74 × 10 8 /kg) and 7.02 × 10 6 /kg CD34+ cells (range, 2.0-25.86 × 10 6 /kg). Prophylaxis and treatment of GvHD were described as before, including tacrolimus, mycophenolate mofetil (MMF), short-term mathotrexate (MTX) and ATG. To prevent GvHD and graft rejection, promote engraftment, umbilical cord blood (UCB) with matched more than in 3/6 HLA loci of 2.0 × 10 7 /kg total nucleated cells before 4-6 h BM given were infused in all patients. 6 All patients had central venous catheters and were cared for in a laminar airflow-equipped room. Antibiotics and supportive care were given empirically for prophylaxis infection and treatmentrelated organ toxicity.
The median follow-up period was 20.1 (range, 11.8-31.1) months. The median time to achieve neutrophil engraftment was 16.0 days (range, 10.0-24.0 days) and platelet 20 days (range, 8.0-120 days) in all patients. The full donor chimeras were achieved within 1 month after transplant in all patients. And a transient mixed chimera was observed in two cases after day 100 of HCT, who recovered to full donor chimera after 1 week of donor lymphocyte infusion (DLI).
Overall, 22 of the 26 patients were alive well. The probability of 1 year OS and disease free survival (DFS) was 84.6% and 80.8%, respectively. Three patients died of pulmonary infection. Only two patients experienced relapse at 165 and 210 days after grafting. One of them achieved continued CR again after undergoing infusion of BM and PBSC followed by high-dose chemotherapy and died of viral myocarditis in 8 months after HSCT. The other one developed minimal residual disease 7 months after transplant and is alive and well up to now. As shown in Figure 1 , the probability of 1 year OS and DFS in patients with myeloid malignancy (including AML, MDS and juvenile myelomonocytic leukemia) and lymphoid (including ALL and LBL) were 90.9%, 80.0%, 90.9% and 75%, respectively, that indicated no significant difference between the two groups. Eight of the 26 patients experienced acute GvHD (aGvHD) after transplant, including 3 with grade I, 4 with grade II, 1 with grade III and none with grade IV. Fourteen patients experienced chronic GvHD (cGvHD), including limited in 13 and extensive in 1. Nine of 13 patients with limited cGvHD were related to the reduction of immunosuppression and DLI. All patients with aGvHD or cGvHD were controlled by symptomatic therapy. Nine patients had documented bacteremia or fungal infection after grafting. Four patients were detected CMV-DNA or EB virus-DNA at 17-47 days after HSCT, but none of them developed CMV disease. Two patients had BK virus-associated hemorrhagic cystitis on day 17 and 28, respectively.
In the final analysis, the purpose of HSCT is to ablate all malignant clone cells in vivo of patients and cure the malignancy. However, disease relapse after transplant for acute leukemia with high risk and refractory is 60 − 80%, both in adults and children. 1, 2, 7 Moreover, the leukemic cells in the majority of relapsed cases originate from consumptive leukemic cells at initial diagnosis, which strongly indicated that the standard myeloablative conditioning regimen could not always kill the residual leukemic stem cells in vivo, particularly those in extramedullary sites. Those residual leukemic stem cells are the culprits for the disease recurrence. Based on the successful experiences either standard HSCT or chemotherapy for these patients. We have previously pioneered the new concept of TAHCT for treatment of those patients with high-risk, refractory, even advanced-stage acute leukemia. 5 The TAHCT involve all parts in procedure of transplantation, the principal contents include individual tumorablative conditioning regimen and enhancing the immunotherapy post transplantation. 5 Here we used the further tumorablative regimen to treat the 26 children with high-risk or relapsed hematologic malignancies. In the median follow-up of 20.1 months, 1 year OS and DFS was 84.6% and 80.8%, respectively, only two patients experienced relapse after grafting. The incidence and severity of GvHD, infection and regimen related toxicity (RRT) were lower and controllable. It indicates that this new strategy is highly effective and tolerated. Our tumorablative conditioning regimen possess the following features: first, it could enhance the intensity of anti-tumor chemotherapy. It included continuous infusion of medium dose Ara-C for 120 h, and drugs with good liposolubility, such as idarubicin and teniposide. The duration of the regimen extended to 14 days, which also ensured a longer manitenance period of effective drug concentrations in extramedullary tissue, and further depletion of leukemic cells in all tissues. Second, adding G-CSF not only increased the sensitivity to the killing effects of drugs by recruiting quiescent leukemic cells into proliferation cycle, but also reduces or alleviates the incidence of post-transplant GvHD through regulating immune cells. Third, the reduction of the dosage of alkylating agent decreased or alleviated the toxic and side effects, under the circumstances of myeloablative and effective immunosuppressant. Lastly, individualization was emphasized, for instance, selecting effective anthracycline according to chemotherapy history of patients.
It is worth mentioning that the UCB matched in more than 3/6 HLA loci were given in all patients in this haploidentical HCT study. The results showed that 30.8% patients experienced aGvHD, only one with grade III and none with grade IV. Fourteen patients experienced cGvHD, extensive in one. All patients with aGvHD or cGvHD were controllable. In previous study, we had demonstrated that UCB as a third part could significantly reduce the incidence and severity of GvHD in HLA mismatched HSCT. 6 The exact mechanism should be deserving of future study.
In summary, the results showed that our new strategy of Haplo-TAHCT in treatment of children with high-risk or relapsed hematologic malignancies had the remarkable advantage in reducing post-transplant relapse, severe aGvHD and treatment-related organ toxicity, which contribute to increasing OS and DFS. Nonetheless, more cases are still required to investigate its effects.
